ADMA Biologics receives Complete Response Letter from FDA for pending BLA
ADMA Biologics announced the FDA has issued a CRL to the Company’s BLA for RI-002, an Intravenous Immune Globulin, for treatment of patients with Primary Humoral Immunodeficiency Disease. The CRL did not cite any concerns with clinical safety and efficacy data. July 29, 2016